Savara Announces New Employment Inducement Grant
22 Marzo 2024 - 2:05PM
Business Wire
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical
company focused on rare respiratory diseases, today announced the
grant of inducement awards to two new employees.
On March 21, 2024, Savara's Board of Directors granted the
inducement awards to two new employees who recently joined the
Company. The inducement awards consist of options to purchase an
aggregate of 125,000 shares of the Company’s common stock and
restricted stock units (RSUs) covering an aggregate of 70,000
shares of the Company’s common stock. These equity awards were
granted under the Savara Inc. 2021 Inducement Equity Incentive Plan
pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules as an
inducement material to the employees’ acceptance of employment with
the Company.
The options have an exercise price of $4.89 per share, the
closing trading price of the Company's common stock on the NASDAQ
Global Market on the grant date. Each option has a 10-year term and
vests as to 1/16th of the number of shares subject to the option on
each quarterly anniversary of the employee’s first day of
employment, subject to the employee’s continued employment on each
such vesting date. 55,000 of the RSUs vest in full on the one-year
anniversary of the employee’s first day of employment, and 15,000
of the RSUs vest in full on the two-year anniversary of the
employee’s first day of employment, subject, in each case, to the
employee’s continued employment on such vesting date.
About Savara
Savara is a clinical stage biopharmaceutical company focused on
rare respiratory diseases. Our lead program, molgramostim nebulizer
solution, is an inhaled granulocyte-macrophage colony-stimulating
factor (GM-CSF) in Phase 3 development for autoimmune pulmonary
alveolar proteinosis (aPAP). Molgramostim is delivered via an
investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our
management team has significant experience in rare respiratory
diseases and pulmonary medicine, identifying unmet needs, and
effectively advancing product candidates to approval and
commercialization. More information can be found at
www.savarapharma.com. (X, formerly known as Twitter: @SavaraPharma,
LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240322650033/en/
Savara Inc. IR & PR Anne Erickson
(anne.erickson@savarapharma.com) (512) 851-1366
Savara (NASDAQ:SVRA)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Savara (NASDAQ:SVRA)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024